Is a cure for hemophilia on the horizon? American biotechnology company BioMarin aims to find out with the help of Sheba Medical Center in Ramat Gan, Israel.
BioMarin has chosen Sheba to take part in the next phase of international trials for what’s being touted as a “magic bullet” cure for hemophilia A, a genetic blood-clotting deficiency that results in patients bleeding longer after an injury and more easily bruising. Hemophilia A, which affects mostly men, can be life-threatening.